Patents by Inventor Daozhong Zou

Daozhong Zou has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11958805
    Abstract: Provided herein are formulations, processes, solid forms and methods of use relating to (E)-1-(4-(1-(((4-cyclohexyl-3-(trifluoromethyl)benzyl)oxy)imino)ethyl)-2-ethylbenzyl)azetidine-3-carboxylic acid.
    Type: Grant
    Filed: August 18, 2020
    Date of Patent: April 16, 2024
    Assignee: NOVARTIS AG
    Inventors: Lianfeng Huang, Daozhong Zou
  • Publication number: 20230250068
    Abstract: The present disclosure provides crystalline forms of a JAK2 inhibitor, compositions thereof and methods of treating a JAK2-mediated disorder.
    Type: Application
    Filed: February 11, 2020
    Publication date: August 10, 2023
    Inventors: Lianfeng Huang, Nancy Tsou, Wenju Wu, Daozhong Zou
  • Publication number: 20230219887
    Abstract: Provided herein are formulations, processes, solid forms and methods of use relating to (E)-1-(4-(1-(((4-cyclohexyl-3-(trifluoromethyl)benzyl)oxy)imino)ethyl)-2-ethylbenzyl)azetidine-3-carboxylic acid.
    Type: Application
    Filed: March 17, 2023
    Publication date: July 13, 2023
    Inventors: Lianfeng HUANG, Daozhong ZOU
  • Patent number: 11629124
    Abstract: Provided herein are formulations, processes, solid forms and methods of use relating to (E)-1-(4-(1-(((4-cyclohexyl-3-(trifluoromethyl)benzyl)oxy)imino)ethyl)-2-ethylbenzyl)azetidine-3-carboxylic acid.
    Type: Grant
    Filed: January 24, 2020
    Date of Patent: April 18, 2023
    Assignee: NOVARTIS AG
    Inventors: Lianfeng Huang, Daozhong Zou
  • Patent number: 11629153
    Abstract: The present invention provides solid forms of an MK2 inhibitor, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: December 29, 2020
    Date of Patent: April 18, 2023
    Assignee: Celgene CAR LLC
    Inventors: Jianxin Han, Lianfeng Huang, Uday Jain, Ying Li, John Malona, Kevin Molter, Chittari Pabba, Alexander L. Ruchelman, Jean Xu, Daozhong Zou
  • Publication number: 20230015251
    Abstract: Provided herein are formulations, processes, solid forms and methods of use relating to (E)-1-(4-(1-(((4-cyclohexyl-3-(trifluoromethyl)benzyl)oxy)imino)ethyl)-2-ethylbenzyl)azetidine-3-carboxylic acid.
    Type: Application
    Filed: August 3, 2022
    Publication date: January 19, 2023
    Inventors: Lianfeng Huang, Daozhong Zou
  • Patent number: 11434200
    Abstract: Provided herein are formulations, processes, solid forms and methods of use relating to (E)-1-(4-(1-(((4-cyclohexyl-3-(trifluoromethyl)benzyl)oxy)imino)ethyl)-2-ethylbenzyl)azetidine-3-carboxylic acid.
    Type: Grant
    Filed: June 18, 2020
    Date of Patent: September 6, 2022
    Assignee: Novartis AG
    Inventors: Lianfeng Huang, Daozhong Zou
  • Patent number: 11186556
    Abstract: Provided herein are formulations, processes, solid forms and methods of use relating to salts of (Z)-5-((Z)-3-chloro-4-((R)-2,3-dihydroxypropoxy)benzylidene)-2-(propylimino)-3-(o-tolyl)thiazolidin-4-one.
    Type: Grant
    Filed: October 15, 2019
    Date of Patent: November 30, 2021
    Assignee: Celgene Corporation
    Inventors: Lianfeng Huang, Daozhong Zou
  • Publication number: 20210198276
    Abstract: The present invention provides solid forms of an MK2 inhibitor, compositions thereof, and methods of using the same.
    Type: Application
    Filed: December 29, 2020
    Publication date: July 1, 2021
    Inventors: Jianxin Han, Lianfeng Huang, Uday Jain, Ying Li, John Malona, Kevin Molter, Chittari Pabba, Alexander L. Ruchelman, Jean Xu, Daozhong Zou
  • Patent number: 11014897
    Abstract: Provided herein are formulations, processes, solid forms and methods of use relating to (Z)-5-((Z)-3-chloro-4-((R)-2,3-dihydroxypropoxy)benzylidene)-2-(propylimino)-3-(o-tolyl)thiazolidin-4-one.
    Type: Grant
    Filed: October 15, 2019
    Date of Patent: May 25, 2021
    Assignee: CELGENE CORPORATION
    Inventors: Lianfeng Huang, Daozhong Zou
  • Patent number: 11013723
    Abstract: Provided herein are formulations, processes, solid forms and methods of use relating to (Z)-5-((Z)-3-chloro-4-((R)-2,3-dihydroxypropoxy)benzylidene)-2-(propylimino)-3-(o-tolyl)thiazolidin-4-one.
    Type: Grant
    Filed: October 15, 2019
    Date of Patent: May 25, 2021
    Assignee: CELGENE CORPORATION
    Inventors: Lianfeng Huang, Daozhong Zou
  • Publication number: 20210139420
    Abstract: Provided herein are formulations, processes, solid forms and methods of use relating to (E)-1-(4-(1-(((4-cyclohexyl-3-(trifluoromethyl)benzyl)oxy)imino)ethyl)-2-ethylbenzyl)azetidine-3-carboxylic acid.
    Type: Application
    Filed: June 18, 2020
    Publication date: May 13, 2021
    Inventors: Lianfeng Huang, Daozhong Zou
  • Patent number: 10882867
    Abstract: The present invention provides solid forms of an MK2 inhibitor, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: March 15, 2018
    Date of Patent: January 5, 2021
    Assignee: Celgene CAR LLC
    Inventors: Jianxin Han, Lianfeng Huang, Uday Jain, Ying Li, John Malona, Kevin Molter, Chittari Pabba, Alexander L. Ruchelman, Jean Xu, Daozhong Zou
  • Publication number: 20200399213
    Abstract: Provided herein are formulations, processes, solid forms and methods of use relating to (E)-1-(4-(1-(((4-cyclohexyl-3-(trifluoromethyl)benzyl)oxy)imino)ethyl)-2-ethylbenzyl)azetidine-3-carboxylic acid.
    Type: Application
    Filed: January 24, 2020
    Publication date: December 24, 2020
    Inventors: Lianfeng Huang, Daozhong Zou
  • Publication number: 20200377454
    Abstract: Provided herein are formulations, processes, solid forms and methods of use relating to (E)-1-(4-(1-(((4-cyclohexyl-3-(trifluoromethyl)benzyl)oxy)imino)ethyl)-2-ethylbenzyl)azetidine-3-carboxylic acid.
    Type: Application
    Filed: August 18, 2020
    Publication date: December 3, 2020
    Inventors: Lianfeng Huang, Daozhong Zou
  • Publication number: 20200148701
    Abstract: The present invention provides solid forms of an MK2 inhibitor, compositions thereof, and methods of using the same.
    Type: Application
    Filed: March 15, 2018
    Publication date: May 14, 2020
    Inventors: Jianxin Han, Lianfeng Huang, Uday Jain, Ying Li, John Malona, Kevin Molter, Chittari Pabba, Alexander L. Ruchelman, Jean Xu, Daozhong Zou
  • Patent number: 10590089
    Abstract: Provided are pharmaceutical compositions and dosage forms of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, or a pharmaceutically acceptable stereoisomer, tautomer, solid form, polymorph, salt, hydrate, clathrate, or solvate thereof. Also provided are methods of treating, managing, or preventing various disorders, such as diseases or disorders treatable or preventable by inhibition of a JNK pathway in mammals using such pharmaceutical compositions or dosage forms. Further provided are salts of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide and methods of preparation of such salts.
    Type: Grant
    Filed: October 2, 2018
    Date of Patent: March 17, 2020
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Nathan Andrew Boersen, Indrajit Ghosh, Lianfeng Huang, Daozhong Zou
  • Patent number: 10202364
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of one or both of ERK1 and ERK2.
    Type: Grant
    Filed: June 14, 2018
    Date of Patent: February 12, 2019
    Assignee: CELGENE CAR LLC
    Inventors: Antonio Christian Ferretti, Lianfeng Huang, Ying Li, John Traverse, Jean Xu, Kelvin Hin-Yeong Yong, Daozhong Zou
  • Publication number: 20190031619
    Abstract: Provided are pharmaceutical compositions and dosage forms of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, or a pharmaceutically acceptable stereoisomer, tautomer, solid form, polymorph, salt, hydrate, clathrate, or solvate thereof. Also provided are methods of treating, managing, or preventing various disorders, such as diseases or disorders treatable or preventable by inhibition of a JNK pathway in mammals using such pharmaceutical compositions or dosage forms. Further provided are salts of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide and methods of preparation of such salts.
    Type: Application
    Filed: October 2, 2018
    Publication date: January 31, 2019
    Inventors: Nathan Andrew BOERSEN, Indrajit GHOSH, Lianfeng HUANG, Daozhong ZOU
  • Publication number: 20180362498
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of one or both of ERK1 and ERK2.
    Type: Application
    Filed: June 14, 2018
    Publication date: December 20, 2018
    Inventors: Antonio Christian Ferretti, Lianfeng Huang, Ying Li, John Traverse, Jean Xu, Kelvin Hin-Yeong Yong, Daozhong Zou